GlobeNewswire by notified

Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023

Share

Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their automated workflow solutions for streamlining discovery workflows in antibody and therapeutics development at Antibody Engineering and Therapeutics, Europe in Amsterdam, The Netherlands. In addition to the exhibition, Jason Lehmann, PhD Senior Product Marketing Manager at Telesis Bio will present “The BioXp® System: Accelerating Hit-to-Lead Discovery by Breaking Through Critical Synthesis Bottlenecks” in the opening day session.

The award winning BioXp® system and associated BioXp De novo kits and BioXp Select kits enable push-button, automated synthesis of gene fragments, clones, variant libraries and mRNA from input sequence or existing DNA. In May, Telesis Bio also introduced their first automated NGS Library Preparation kit for Plasmid Sequencing on the BioXp platform, further advancing the vision of the platform as a total solution for streamlining molecular biology workflows. The BioXp system empowers researchers in antibody therapeutics to overcome traditional bottlenecks in lead discovery programs and take control of their synthesis timelines by enabling automated and efficient synthesis and sequence confirmation of antibody candidates.

For more information on solutions for accelerating workflows in therapeutic antibody development, please visit https://telesisbio.com/workflows/synthetic-dna/antibody-drug-discovery/

About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.

Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding the anticipated use of proceeds from the financing, as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (SEC) on March 22, 2023, as amended on May 17, 2023 and in our Quarterly Report on Form 10-Q, which was filed with the SEC on May 12, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

Contact:
Jen Carroll
Vice President of Investor Relations
jen.carroll@telesisbio.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Northland Power Announces Financial Close of the 1.1 GW Baltic Power Offshore Wind Project in Poland Green Financing22.9.2023 22:33:21 CEST | Press release

TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI), today announced that its Baltic Power offshore wind project (“Baltic Power” or the “project”) in Poland has met all conditions and reached financial close for its 20-year CAD-equivalent $5.2 billion non-recourse green financing. A consortium of 25 financial institutions is supporting the project, including the European Investment Bank (EIB), European Bank for Reconstruction and Development (EBRD), Euler Hermes, Export and Investment Fund of Denmark and Export Development Canada. Baltic Power will play an important role in helping the Polish government achieve its renewable energy target where installed capacity of offshore wind energy is expected to reach up to 11 GW by 2040. Once operational, Baltic Power is expected to provide clean energy to more than 1.5 million Polish households annually. ABOUT NORTHLAND POWER Northland Power is a global power producer dedicated to helping t

Brookfield Corporation Announces Results of Conversion of its Series 32 Preferred Shares22.9.2023 22:05:00 CEST | Press release

BROOKFIELD, NEWS, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Brookfield Corporation (NYSE: BN, TSX: BN) today announced that after having taken into account all election notices received by the deadline for the conversion of its Cumulative Class A Preference Shares, Series 32 (the “Series 32 Shares”) (TSX: BN.PF.A) into Cumulative Class A Preference Shares, Series 33 (the “Series 33 Shares”), there were 177,688 Series 32 Shares tendered for conversion, which is less than the one million shares required to give effect to conversion into Series 33 Shares. Accordingly, there will be no conversion of Series 32 Shares into Series 33 Shares and holders of Series 32 Shares will retain their Series 32 Shares. About Brookfield Corporation Brookfield Corporation (NYSE: BN, TSX: BN) is focused on compounding capital over the long term to earn attractive total returns for our shareholders. Today, our capital is deployed across three businesses – Asset Management, Insurance Solutions and our Operating Busi

Monument Achieves Commercial Production at Selinsing Gold Mine22.9.2023 20:11:07 CEST | Press release

VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) ("Monument" or the "Company") is pleased to announce that commercial production has been achieved at the Selinsing Gold Mine in Malaysia that has operated 30 days consecutive production of gold concentrate at 90% of designed capacity. Cathy Zhai, President and CEO of Monument Mining commented: "We are very pleased to announce this landmark event at the Selinsing gold mine. After 12 years gold bullion production that generated positive cash flow, now the Gold Sulphide Project will continue the legacy, based on such we move forward to the Murchison Gold Project and the corporate development as well. We thank the Monument Mining team and contractor partners for their dedication and hard work to achieve this commercial production milestone.” Figure 1: Selinsing Flotation Plant at Night is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c385faa-226d-480e-b975-

Nokia Corporation: Repurchase of own shares on 22.09.202322.9.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 22 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 22.09.2023 Espoo, Finland – On 22 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL328,9913.65CEUX40,7873.66AQEU12,5813.66TQEX5,6413.66Total388,0003.65 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar

Fingerprint Cards AB (publ) offentliggör slutligt utfall i utnyttjandet av teckningsoptioner av serie 2022:1 och 2022:222.9.2023 19:00:00 CEST | Pressemelding

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, INOM ELLER TILL USA (INKLUSIVE DESS TERRIRTORIER OCH BESITTNINGAR), AUSTRALIEN, JAPAN, KANADA, HONGKONG, NYA ZEELAND, SINGAPORE ELLER SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA OLAGLIGT ELLER KRÄVA REGISTERING ELLER ANDRA ÅTGÄRDER ENLIGT GÄLLANDE LAG. ANDRA RESTRIKTIONER ÄR TILLÄMPLIGA. VÄNLIGEN SE AVSNITTET "VIKTIG INFORMATION" I SLUTET AV DETTA PRESSMEDDELANDE. Fingerprint Cards AB:s (publ) (“Fingerprints” eller “Bolaget”) offentliggör utfallet från utnyttjandet av teckningsoptionerna av serie 2022:1 och 2022:2 (”Teckningsoptionerna”), vilka emitterades i samband med Bolagets företrädesemission av units under november/december 2022. Totalt utnyttjades 2 708 761 teckningsoptioner av serie 2022:2, motsvarande cirka 13,7 procent av utestående teckningsoptioner av serie 2022:2, till en teckningskurs om 1,30 SEK styck som berättigar till 1,03 B-aktier. Totalt t